Patient-Focused Drug Development Guidance: Determining When A Clinical Outcome Assessment Is Appropriate
Executive Summary
A US FDA draft guidance on selecting and developing fit-for-purpose clinical outcome assessments specifies the evidence that can be provided to support using a COA in a particular context.
You may also be interested in...
Standardization Of Patient-Focused Core Clinical Outcomes Could Enable Labeling Comparisons
US FDA’s Theresa Mullin envisions having a national catalog of standard core clinical outcomes assessment measures that could apply to every disease area.
Social Media Data Gains Prominence In Patient-Focused Drug Development
FDA guidances have provided ‘major step forward’ for use of social media data, Roche researcher notes. Agency staffer offers checklist for collecting patient experience data in this realm.
Missing Data Hinders Inclusion Of Patient Experience In Drug Labeling, US FDA Says
Agency staff note hurdles in obtaining evidence outlined in FDA’s patient-focused drug development guidance to support regulatory decision-making.